Lupin Launches Dapagliflozin Tablets in U.S. Market
Mumbai, India & Naples, Florida | April 10, 2026 Lupin Limited has announced the U.S. launch of Dapagliflozin Tablets...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Mumbai, India & Naples, Florida | April 10, 2026 Lupin Limited has announced the U.S. launch of Dapagliflozin Tablets...
MUMBAI, India and NAPLES, Fla., April 7, 2026 Lupin Limited has received approval from the U.S. Food and Drug...
MUMBAI, India & NAPLES, Fla., USA, March 31, 2026 Lupin Limited has received tentative approval from the U.S. Food...
MUMBAI, INDIA & NAPLES, USA | March 25, 2026 Lupin Limited, a global pharmaceutical leader, has received tentative approval...
February 24, 2026 – Pittsburgh, Pennsylvania, USA Consegna Pharma, Inc. has announced that the U.S. Food and Drug Administration...
February 24, 2026 – Mumbai, India & Naples, Florida, USA Global pharmaceutical leader Lupin Limited has announced that it...
MUMBAI, India & NAPLES, Fla., Feb. 4, 2026 — Global pharmaceutical company Lupin Limited announced the U.S. launch of...
Dateline: November 14, 2025 — Mumbai, India / Baltimore, MarylandLupin has launched its Risperidone Long-Acting Injectable (LAI) in the...
